Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Post by 1ottrunneron Apr 23, 2021 6:34am
142 Views
Post# 33053655

Why so many sites?

Why so many sites?

Is enrollment really so slow that RVV needs 50 sites to recruite the remaining < 800 patients?
That is just 16 patients per site?

I asked MF if the dose had been decided and he had no comment, sadly.  
The interim data must have a setpoint, 400?  RVV would need to complete that enrollment, plus 28 days for the course of treatment, plus data collection.  It would seems that 60 days minimum would be needed.

-->Has the 400 been reached and they are collected data?  Are they collected data as they go?

--->What is the driver for the added sites, the study was initially 10 sites.

The trial would\will be put to rest if the interim data is not good.  Why spend funds to add sites unless some glimmer of response has been seen.  It points to positivity.  

This company is a major player in the Psilocybin market, that will be enough to support any investment at this level and drive it back to near or more than a dollar on any market hype around Psilocybin.  In the past 2 weeks while the PSYK index took a beating RVV has stayed reasonably afloat.  When it recovers RVV will lead the group.

 

<< Previous
Bullboard Posts
Next >>